The ABHD10 Knockout SK-HEP-1 Polyclonal Cells comprise a CRISPR/Cas9?edited polyclonal knockout cell population targeting the ABHD10 gene in the human hepatocellular carcinoma SK?HEP?1 cell line. Unlike clonal isolates, this polyclonal product offers a heterogeneous mixture of Abhd10?disrupted cells, minimizing clone?specific artifacts and capturing a broader spectrum of loss?of?function phenotypes. It provides a robust, mixed genetic background platform for interrogating mitochondrial deglycosylation processes in a liver cancer context.
SK?HEP?1 cells originated from the ascitic fluid of a patient with adenocarcinoma of the liver and are firmly established as a model for hepatocellular carcinoma studies. They display characteristic epithelial morphology and metabolic deregulation, including enhanced glycolytic and glutaminolytic activities. Their wide use in cancer research spans investigations of signal transduction, metabolic reprogramming, and drug sensitivity, rendering them an appropriate host for probing mitochondrial protein modifications.
ABHD10 functions as a mitochondrial ??/?? hydrolase with O?GlcNAcase activity, catalyzing the removal of O?GlcNAc from target proteins. It operates in concert with O?GlcNAc transferase (OGT), which adds the modification, to regulate reversible O?GlcNAcylation cycles. ABHD10 is regulated upstream by stress?responsive transcription factors and O?GlcNAc cycling enzymes, and its translocation into mitochondria depends on the mitochondrial import machinery and chaperones. Downstream, ABHD10 de?glycosylates a subset of O?GlcNAc?modified mitochondrial proteins, among them apoptotic regulators, thereby influencing mitochondrial homeostasis and programmed cell death. Through these interactions, ABHD10 serves as a critical node in the pathway: OGT ?? O?GlcNAc ?? ABHD10 ?? mitochondrial proteins.
In SK?HEP?1 hepatocellular carcinoma cells, ABHD10 knockout disrupts mitochondrial O?GlcNAc dynamics, leading to aberrant accumulation of O?GlcNAcylated proteins. This dysregulation can impair mitochondrial protein quality control, alter cristae architecture, and sensitize cells to apoptotic stimuli. The model highlights the impact of disrupted deglycosylation on cancer metabolism and may unveil therapeutic vulnerabilities related to mitochondrial dysfunction in liver tumors.
Researchers can leverage these polyclonal knockout cells to investigate mitochondrial O?GlcNAcylation in liver cancer, using assays such as western blotting for ABHD10 and global O?GlcNAc, RT?qPCR for transcript verification, immunofluorescence for mitochondrial morphology, and flow cytometry for apoptosis. Metabolic flux analysis enables profiling of glycolytic and oxidative pathways. The cells are also applicable to co?immunoprecipitation of O?GlcNAc?modified proteins and drug screening for glycosylation modulators. For technical inquiries and batch?specific data, please contact Ascent Research.
